|Bid||57.00 x 1200|
|Ask||59.25 x 800|
|Day's Range||57.97 - 60.49|
|52 Week Range||19.51 - 73.72|
|Beta (5Y Monthly)||1.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 23, 2020 - Nov 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.64|
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) rose sharply on Thursday and closed today's trading session up 9.9% after climbing by as much as 14.4%. The drugmaker did not report any news, but biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX) released an update regarding one of its pipeline candidates, and the update bodes well for Arrowhead and its shareholders. On Wednesday evening, Vertex announced it would discontinue the development of VX-814, a potential treatment for alpha-1 antitrypsin deficiency (AATD), a genetic condition that can cause lung or liver disease.
Shares of Vertex plunged after hours Wednesday after the company announced it planned to stop testing on a drug designed to treat protein deficiencies. VRTX stock fell by double digits.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q3 sales of $27.38 million. Earnings fell to a loss of $15.95 million, resulting in a 28.3% decrease from last quarter. Arrowhead Pharmaceuticals collected $23.53 million in revenue during Q2, but reported earnings showed a $22.24 million loss.What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Arrowhead Pharmaceuticals posted an ROCE of -0.03%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on ARWRROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Arrowhead Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In Arrowhead Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q3 Earnings Recap Arrowhead Pharmaceuticals reported Q3 earnings per share at $-0.13/share, which did not meet analyst predictions of $-0.12/share.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * 12 Healthcare Stocks Moving In Thursday's Pre-Market Session * Looking Into Arrowhead Pharmaceuticals's Return On Capital Employed(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.